Biosynthesis and deposition of a noncovalent laminin-heparan sulfate proteoglycan complex and other basal lamina components by a human malignant cell line.
The basal lamina components laminin, heparan sulfate proteoglycan (HSPG), and type IV collagen were synthesized and codeposited in the extracellular matrix (ECM) by a cultured human cell line from gestational choriocarcinoma (JAR). Laminin and HSPG formed a noncovalent complex detected by the coimmunoprecipitation of HSPG with laminin from cell lysates and culture media. The complex was stable in the cell lysis buffer that contained detergents (1% Triton X-100, 0.5% deoxycholate, and 0.1% sodium dodecyl sulfate) and sodium chloride (from 0.15 to 1.0 M), but was dissociated by adding 8 M urea to the detergent lysates. Even though JAR cells produced roughly equal amounts of HSPG and chondroitin sulfate proteoglycan, only HSPG complexed with laminin, suggesting a specific interaction between these basal lamina components. The laminin-HSPG complex was deposited and retained in the ECM. This was shown biochemically by isolating an enriched fraction of ECM from JAR cells cultured on native type I collagen gels. At steady state, more than half (52%) of the laminin-HSPG in the culture was recovered in the ECM fraction, in contrast to 16% of the total laminin and 29% of the total type IV collagen, which were secreted to a greater extent than laminin-HSPG into the culture medium. The retention of the laminin-HSPG complex in the ECM suggests that it may participate in the assembly of the basal lamina-like extracellular matrix deposited by JAR cultures. Omission of ascorbate from the culture medium abolished the ECM deposition of type IV collagen but had little effect on the deposition of laminin or laminin-HSPG. This demonstrates that the stable deposition of laminin-HSPG and laminin in the collagen-based choriocarcinoma cultures is not dependent on an assembled network of type IV collagen.
Frenette
G P
GP
Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0626.
Ruddon
R W
RW
Krzesicki
R F
RF
Naser
J A
JA
Peters
B P
BP
D001485:Basement Membrane / Q000378:metabolism; D002809:Chondroitin Sulfates / Q000378:metabolism; D002822:Choriocarcinoma / Q000378:metabolism; D003094:Collagen / Q000096:biosynthesis; D003902:Detergents / Q000494:pharmacology; D004591:Electrophoresis, Polyacrylamide Gel; D005109:Extracellular Matrix / Q000378:metabolism*; D005260:Female; D006025:Glycosaminoglycans / Q000096:biosynthesis / Q000378:metabolism; D006493:Heparin / Q000031:analogs & derivatives* / Q000378:metabolism; D006801:Humans; D007163:Immunosorbent Techniques; D007700:Kinetics; D007797:Laminin / Q000378:metabolism*; D046911:Macromolecular Substances; D011247:Pregnancy; D011402:Pronase / Q000378:metabolism; D011509:Proteoglycans / Q000378:metabolism*; D012965:Sodium Chloride / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014508:Urea / Q000494:pharmacology; D014594:Uterine Neoplasms / Q000378:metabolism
D003902:Detergents; D006025:Glycosaminoglycans; D007797:Laminin; D046911:Macromolecular Substances; D011509:Proteoglycans; C038142:chondroitin sulfate glycosaminoglycan; C036090:heparin proteoglycan; D012965:Sodium Chloride; D014508:Urea; D006493:Heparin; D002809:Chondroitin Sulfates; D003094:Collagen; D011402:Pronase